Upgrade to SI Premium - Free Trial

HELP (HELP)

12.22 +0.45 (3.82%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York September 3, 2026 7:30 AM - StreetInsider Helus Pharma (HELP) PT Raised to $62 at TD Cowen August 20, 2026 6:03 AM - StreetInsider Form D CYBIN INC. August 19, 2026 5:02 PM - SEC Filing Form D CYBIN INC. August 19, 2026 5:00 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Helus Pharma (HELP) August 19, 2026 6:48 AM - StreetInsider Form 6-K CYBIN INC. For: Aug 18 August 19, 2026 6:04 AM - SEC Filing Form 6-K CYBIN INC. For: Aug 18 August 18, 2026 11:43 AM - SEC Filing Helus Pharma names chief people officer, adds CNS expert to advisory board August 18, 2026 7:30 AM - StreetInsider Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board August 18, 2026 7:30 AM - StreetInsider Form SCHEDULE 13G/A CYBIN INC. Filed by: Sirenia Capital Management LP August 14, 2026 8:32 AM - SEC Filing Form 6-K CYBIN INC. For: Aug 14 August 14, 2026 7:44 AM - SEC Filing Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights August 14, 2026 7:28 AM - Globe NewsWire Form SCHEDULE 13G CYBIN INC. Filed by: Adage Capital Management, L.P. August 12, 2026 12:10 PM - SEC Filing Form 6-K CYBIN INC. For: Aug 10 August 11, 2026 6:01 AM - SEC Filing Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston August 10, 2026 12:00 PM - StreetInsider Helus Pharma names ex-Intra-Cellular president as CEO August 5, 2026 10:26 AM - StreetInsider A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout August 5, 2026 10:25 AM - Globe NewsWire Form 6-K CYBIN INC. For: Aug 03 August 3, 2026 10:26 AM - SEC Filing Helus Pharma names former Intra-Cellular president as new CEO August 3, 2026 7:41 AM - StreetInsider Helus Pharma Appoints Michael Halstead as Chief Executive Officer August 3, 2026 7:40 AM - StreetInsider Wells Fargo sees psychedelics market reaching $11B by 2035 July 27, 2026 6:55 AM - StreetInsider Wells Fargo Starts Cybin Inc. (HELP) at Overweight July 27, 2026 5:44 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Helus Pharma (HELP) July 22, 2026 6:52 AM - StreetInsider Form 6-K CYBIN INC. For: Jul 21 July 21, 2026 5:16 PM - SEC Filing Helus Pharma completes enrollment in phase 3 depression study July 21, 2026 10:55 AM - StreetInsider Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule July 21, 2026 10:55 AM - PR NewsWire Helus Pharma completes enrollment in Phase 3 depression study July 21, 2026 7:50 AM - StreetInsider Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule July 21, 2026 7:50 AM - StreetInsider Helus Pharma (HELP) PT Lowered to $45 at Guggenheim July 17, 2026 7:05 AM - StreetInsider Form 6-K CYBIN INC. For: Jun 26 July 16, 2026 3:17 PM - SEC Filing Form D CYBIN INC. July 16, 2026 6:03 AM - SEC Filing Form D CYBIN INC. July 16, 2026 6:03 AM - SEC Filing Helus Pharma (HELP) PT Lowered to $70 at H.C. Wainwright July 9, 2026 6:47 AM - StreetInsider Helus Pharma (HELP) PT Lowered to $42 at Canaccord July 1, 2026 6:34 AM - StreetInsider Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity June 30, 2026 9:00 AM - StreetInsider Form 6-K CYBIN INC. For: Jun 29 June 29, 2026 5:10 PM - SEC Filing Helus Pharma reports $148M net loss, closes $50M offering June 29, 2026 7:43 AM - StreetInsider Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results June 29, 2026 7:40 AM - StreetInsider Form 40-F CYBIN INC. For: Mar 31 June 29, 2026 7:36 AM - SEC Filing Form 6-K CYBIN INC. For: Jun 25 June 25, 2026 11:05 AM - SEC Filing Helus Pharma closes $50M share offering at $4.85 per share June 25, 2026 9:52 AM - StreetInsider Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering June 25, 2026 9:28 AM - StreetInsider Form SUPPL CYBIN INC. June 25, 2026 6:02 AM - SEC Filing Form 6-K CYBIN INC. For: Jun 23 June 25, 2026 6:02 AM - SEC Filing Form FWP CYBIN INC. Filed by: CYBIN INC. June 24, 2026 6:02 AM - SEC Filing Helus Pharma prices $50M share offering at $4.85 per share June 24, 2026 6:01 AM - StreetInsider Helus Pharma™ Announces US$50 Million Underwritten Offering June 24, 2026 6:01 AM - Globe NewsWire Helus Pharma™ Announces US$50 Million Underwritten Offering June 24, 2026 6:01 AM - StreetInsider Helus Pharma Phase 3 MDD trial surpasses 86% enrollment June 24, 2026 6:00 AM - StreetInsider Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress June 24, 2026 6:00 AM - StreetInsider Form 6-K CYBIN INC. For: Jun 11 June 11, 2026 2:35 PM - SEC Filing Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference June 11, 2026 7:30 AM - StreetInsider Full Article List